Clinical Trials Browser

Phase 2 × tremelimumab × Gastrointestinal × Clear all

NCT06855225 2026-04-17

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Liver Neoplasms

NCT06880523 2026-04-14

SLIDE-HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT02888743 2026-04-13

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Phase 2 Active not recruiting

110 enrolled 21 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07511504 2026-04-06

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03937830 2026-03-24

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04522544 2026-02-18

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT02519348 2026-02-17

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Phase 2 Active not recruiting

433 enrolled 26 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT07174570 2026-01-28

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06526104 2026-01-06

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis

NCT07081633 2025-12-30

TREMENDOUS-2

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04430452 2025-12-08

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04238637 2025-12-05

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Phase 2 Active not recruiting

Gastrointestinal

Cholangiocarcinoma

NCT06994299 2025-11-18

PRISM

Phase 2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT06698250 2025-11-06

ZENOBIA

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06999694 2025-09-10

Proton-STRIDE

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03638141 2025-08-17

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Phase 2 Completed

21 enrolled 12 charts

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT07122089 2025-08-14

IOSPHERE

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05451043 2025-06-26

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT04817826 2025-06-10

INFINITY

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms, Microsatellite Instability

NCT06999707 2025-06-05

Photon-STRIDE

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05239169 2025-05-01

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT06045975 2025-04-02

DUMELEP

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05027425 2024-11-22

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Phase 2 Active not recruiting

Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal

NCT06017297 2024-11-12

ESR-22-21719

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

NCT06680739 2024-11-08

SERPENTINE

Phase 2 Recruiting

GastrointestinalGynecologic

Colorectal Neoplasms, Endometrial Neoplasms

NCT05440864 2024-10-10

(NEOTOMA)

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04156087 2024-09-19

MIMIPAC

Phase 2 Completed

Gastrointestinal

Pancreatic Cancer Non-resectable

NCT00378482 2024-08-22

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Phase 2 Completed

37 enrolled 13 charts

DermatologicGastrointestinalGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT05844046 2024-07-16

MONTBLANC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03959293 2024-07-08

Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT04159974 2024-05-09

RICE

Phase 2 Unknown

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT03046862 2024-04-19

Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer

Phase 2 Active not recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT02870920 2023-12-08

Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer

Phase 2 Completed

180 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT04988945 2023-09-06

TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03473574 2023-06-15

IMMUCHEC

Phase 2 Completed

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT05809869 2023-04-12

Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT02821754 2023-03-28

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Phase 2 Completed

54 enrolled 14 charts

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Cholangiocarcinoma

NCT03982173 2023-01-26

MATILDA

Phase 2 Withdrawn

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03007407 2022-12-05

Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy

Phase 2 Completed

33 enrolled 8 charts

Gastrointestinal

Colorectal Cancer Metastatic

NCT03482102 2022-09-08

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT03122509 2022-07-06

A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer

Phase 2 Completed

25 enrolled 7 charts

Gastrointestinal

Colorectal Neoplasms

NCT03101475 2022-05-31

ILOC

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT03377400 2020-12-17

Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Phase 2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT00313794 2012-06-07

Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms